Long-Circulating Lipid Nanospheres Loaded with Flurbiprofen Axetil for Targeted Rheumatoid Arthritis Treatment
Zhenyu Chen,Zhongbing Liu,Shuzao Wang,Cai Cheng,Xiaoduan Sun,Zerong Liu,Jun Wei,Jun Jiang,Huaqi Lan,Meiling Zhou,Pei Jing,Yan Lin,Xiangyu Zhou,Zhirong Zhong
DOI: https://doi.org/10.2147/IJN.S419502
IF: 7.033
2023-09-09
International Journal of Nanomedicine
Abstract:Zhenyu Chen, 1, 2, &ast Zhongbing Liu, 1, &ast Shuzao Wang, 1, &ast Cai Cheng, 1, &ast Xiaoduan Sun, 1 Zerong Liu, 3 Jun Wei, 1 Jun Jiang, 4, 5 Huaqi Lan, 1 Meiling Zhou, 6 Pei Jing, 6 Yan Lin, 1 Xiangyu Zhou, 7 Zhirong Zhong 1, 3, 8 1 Key Laboratory of Medical Electrophysiology, Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China; 2 The Second People's Hospital of China Three Gorges University, Yichang, 443000, People's Republic of China; 3 Central Nervous System Drug Key Laboratory of Sichuan Province, Luzhou, Sichuan, 646000, People's Republic of China; 4 Department of General Surgery (Thyroid Surgery), the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China; 5 Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Luzhou, Sichuan, 646000, People's Republic of China; 6 Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China; 7 Department of Thyroid and Vascular Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China; 8 Key Laboratory of Luzhou City for Aging Medicine, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiangyu Zhou; Zhirong Zhong, Email ; Background: Flurbiprofen axetil (FA) is a non-steroidal anti-inflammatory drug with good analgesic and anti-inflammatory effects. However, it suffers from poor solubility, short circulation time, and off-target binding profile, which significantly limit its clinical application. Here, we loaded FA into stealth lipid microspheres modified with the arginine-glycine-aspartic acid (RGD) peptide (cRGD-FA-SLM), and examined the therapeutic potential of the resulting platform for the treatment of rheumatoid arthritis (RA). Methods: cRGD-FA-SLM was prepared by high pressure homogenization, and its toxicity and uptake by macrophages were examined using cultures of RAW264.7 cells. Hemolysis and hepatotoxicity tests were performed to assess the safety of the developed platform, while its pharmacokinetics, biodistribution, and therapeutic efficacy were investigated in a collagen-induced arthritis rat model. Results: cRGD-FA-SLM showed homogeneous spherical morphology and efficient encapsulation of FA. The developed platform was non-toxic to normal macrophages and was selectively internalized by lipopolysaccharide-activated macrophages in vitro, while it distributed mainly to arthritic joints and significantly prolonged FA in circulation in vivo. cRGD-FA-SLM also significantly reduced the expression of prostaglandin E2 and alleviated joint edema and bone erosion, showing prolonged analgesic effects in arthritic rats. Conclusion: cRGD-FA-SLM shows good inflammation-targeting ability and prolongs drug circulation in vivo, suggesting promise as an anti-inflammatory and analgesic agent for targeted RA treatment. Graphical Keywords: flurbiprofen axetil, lipid nanospheres, cRGD, long circulation, rheumatoid arthritis Graphical Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic symmetry and chronic inflammation of the joints. 1 Chronic synovitis, synovial cell hyperplasia, and vascular opacification predominate at the site of inflammation, 2,3 but how genetics, infections or other factors contribute to the disease is unclear. 4 The current first-line treatment against RA is non-steroidal anti-inflammatory drugs (NSAIDs) such as flurbiprofen axetil (FA), glucocorticoids, disease-modifying anti-rheumatic drugs, and biologic anti-rheumatic drugs. 5,6 These drugs are quite effective at relieving pain, inflammation and stiffness in RA, delaying disease progression, maintaining joint function and reducing disability. 7 In fact, NSAIDs show stronger anti-inflammatory and analgesic effects than many other RA treatments. 8 However, NSAIDs do not specifically target inflamed tissue, increasing risk of adverse systemic effects such as gastrointestinal toxicities, cardiovascular risks, renal injuries, and hepatotoxicity as well as hypertension and other minor disorders. Although there are various distinctive treatment methods for RA, 9, -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology